Psychedelic Drug Developers Go Public

When New York-based psychedelic drug developer MindMed went public this week, they sought funding to continue work on mental health treatment that looks to LSD (a Schedule 1 drug) as its active ingredient. They’re the second psychedelics company to go down this financial path in the US, with a third not far behind. This news warrants attention because of the lack of legalization for psychedelics …